|
US4673641A
(en)
|
1982-12-16 |
1987-06-16 |
Molecular Genetics Research And Development Limited Partnership |
Co-aggregate purification of proteins
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
ATE222291T1
(de)
|
1992-03-13 |
2002-08-15 |
Organon Teknika Bv |
Epstein-barr-virus verwandte peptide und nukleinsäuresegmenten
|
|
US5770565A
(en)
|
1994-04-13 |
1998-06-23 |
La Jolla Cancer Research Center |
Peptides for reducing or inhibiting bone resorption
|
|
US5688781A
(en)
|
1994-08-19 |
1997-11-18 |
Bristol-Myers Squibb Company |
Method for treating vascular leak syndrome
|
|
EP1445322B2
(en)
|
1995-06-15 |
2012-06-06 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
|
US20030040463A1
(en)
|
1996-04-05 |
2003-02-27 |
Wiegand Stanley J. |
TIE-2 ligands, methods of making and uses thereof
|
|
WO1998018914A1
(en)
|
1996-10-31 |
1998-05-07 |
Duke University |
Soluble tie2 receptor
|
|
JPH11225351A
(ja)
|
1998-02-04 |
1999-08-17 |
Matsushita Electric Ind Co Ltd |
ページャー機能を備える無線通信装置のメッセージ消去方法および装置
|
|
US5980929A
(en)
|
1998-03-13 |
1999-11-09 |
Johns Hopkins University, School Of Medicine |
Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
|
|
US5919813C1
(en)
|
1998-03-13 |
2002-01-29 |
Univ Johns Hopkins Med |
Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
|
|
AR022303A1
(es)
|
1999-01-22 |
2002-09-04 |
Lundbeck & Co As H |
Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
|
|
ATE412433T1
(de)
*
|
1999-02-12 |
2008-11-15 |
Scripps Research Inst |
Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
|
|
US6455035B1
(en)
|
1999-03-26 |
2002-09-24 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietins and methods of use thereof
|
|
EP1165115B1
(en)
|
1999-03-26 |
2003-05-28 |
Regeneron Pharmaceuticals, Inc. |
Modulation of vascular permeability by mean of tie2 receptor activators
|
|
EP1046715A1
(en)
|
1999-04-23 |
2000-10-25 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
|
|
AU5062500A
(en)
|
1999-04-26 |
2000-11-10 |
Amersham Pharmacia Biotech Ab |
Primers for identifying typing or classifying nucleic acids
|
|
WO2000064946A2
(en)
|
1999-04-28 |
2000-11-02 |
Board Of Regents, The University Of Texas System |
Compositions and methods for cancer treatment by selectively inhibiting vegf
|
|
AU5147700A
(en)
|
1999-05-19 |
2000-12-05 |
Amgen, Inc. |
Crystal of a lymphocyte kinase-ligand complex and methods of use
|
|
ES2252058T3
(es)
|
1999-08-27 |
2006-05-16 |
Sugen, Inc. |
Mimicos de fosfato y metodos de tratamiento empleando inhibidores de fosfatasa.
|
|
US6589758B1
(en)
|
2000-05-19 |
2003-07-08 |
Amgen Inc. |
Crystal of a kinase-ligand complex and methods of use
|
|
KR20080068151A
(ko)
|
2000-06-23 |
2008-07-22 |
바이엘 쉐링 파마 악티엔게젤샤프트 |
ＶＥＧＦ/ＶＥＧＦ 수용체 및 안지오포이에틴/Ｔｉｅ수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ)
|
|
CZ2003788A3
(cs)
|
2000-09-27 |
2003-08-13 |
The Procter & Gamble Company |
Ligandy melanokortinového receptoru
|
|
AU2002335085A1
(en)
|
2001-10-25 |
2003-05-06 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietins and methods of use thereof
|
|
WO2003084565A2
(en)
|
2002-04-08 |
2003-10-16 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Ve-ptp as regulator of ve-cadherin mediated processes or disorders
|
|
AU2003231098A1
(en)
|
2002-04-25 |
2003-11-10 |
University Of Connecticut Health Center |
Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
|
|
US7507568B2
(en)
|
2002-09-25 |
2009-03-24 |
The Proctor & Gamble Company |
Three dimensional coordinates of HPTPbeta
|
|
US7226755B1
(en)
|
2002-09-25 |
2007-06-05 |
The Procter & Gamble Company |
HPTPbeta as a target in treatment of angiogenesis mediated disorders
|
|
US6946479B2
(en)
|
2002-11-09 |
2005-09-20 |
The Procter & Gamble Company |
N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
|
|
US6930117B2
(en)
|
2002-11-09 |
2005-08-16 |
The Procter & Gamble Company |
N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
|
|
US20040167183A1
(en)
|
2003-02-20 |
2004-08-26 |
The Procter & Gamble Company |
Phenethylamino sulfamic acids
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
US20050158320A1
(en)
*
|
2003-11-12 |
2005-07-21 |
Nichols M. J. |
Combinations for the treatment of proliferative diseases
|
|
US8298532B2
(en)
|
2004-01-16 |
2012-10-30 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
|
LT2653465T
(lt)
|
2004-03-15 |
2016-09-12 |
Janssen Pharmaceutica Nv |
Opioidinio receptoriaus moduliatoriai
|
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
|
EP1771474B1
(en)
|
2004-07-20 |
2010-01-27 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
|
DK2457578T3
(en)
|
2004-09-28 |
2015-12-07 |
Aprogen Inc |
A chimeric molecule comprising angiopoietin-1 and a coiled-coil domain for use in the treatment of erectile dysfunction of the penis
|
|
WO2006068953A2
(en)
|
2004-12-21 |
2006-06-29 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
|
US20060241076A1
(en)
*
|
2005-04-26 |
2006-10-26 |
Coley Pharmaceutical Gmbh |
Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
|
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
|
US7893040B2
(en)
|
2005-07-22 |
2011-02-22 |
Oculis Ehf |
Cyclodextrin nanotechnology for ophthalmic drug delivery
|
|
US20070154482A1
(en)
|
2005-09-12 |
2007-07-05 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
|
EP3168234A1
(en)
|
2005-12-15 |
2017-05-17 |
Medimmune Limited |
Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
|
|
US7588924B2
(en)
|
2006-03-07 |
2009-09-15 |
Procter & Gamble Company |
Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
|
|
ES2828739T3
(es)
|
2006-04-07 |
2021-05-27 |
Aerpio Pharmaceuticals Inc |
Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
|
|
US20130023542A1
(en)
|
2006-06-27 |
2013-01-24 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7589212B2
(en)
|
2006-06-27 |
2009-09-15 |
Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7622593B2
(en)
*
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US8846685B2
(en)
|
2006-06-27 |
2014-09-30 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7795444B2
(en)
|
2006-06-27 |
2010-09-14 |
Warner Chilcott Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US8957022B2
(en)
|
2006-10-27 |
2015-02-17 |
Sunnybrook Health Sciences Centre |
Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
|
|
US8642067B2
(en)
|
2007-04-02 |
2014-02-04 |
Allergen, Inc. |
Methods and compositions for intraocular administration to treat ocular conditions
|
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
|
WO2009105774A2
(en)
|
2008-02-21 |
2009-08-27 |
Sequoia Pharmaceuticals, Inc. |
Amino acid inhibitors of cytochrome p450
|
|
US9096555B2
(en)
|
2009-01-12 |
2015-08-04 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome
|
|
DK2385763T3
(en)
|
2009-01-12 |
2018-07-16 |
Aerpio Therapeutics Inc |
METHODS OF TREATING VASCULAR LEAK SYNDROME
|
|
CA2753690A1
(en)
|
2009-03-03 |
2010-09-10 |
Alcon Research, Ltd. |
Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
|
|
EP2403342A4
(en)
|
2009-03-03 |
2013-06-05 |
Alcon Res Ltd |
PHARMACEUTICAL COMPOSITION FOR IL-ADMINISTRATION OF TYROSINE KINASE RECEPTOR INHIBITING COMPOUNDS (RTKI)
|
|
US8569348B2
(en)
|
2009-07-06 |
2013-10-29 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
|
PH12012500788A1
(en)
|
2009-11-06 |
2016-07-27 |
Aerpio Therapeutics Inc |
Compositions and methods for treating colitis
|
|
MX2012014428A
(es)
|
2010-07-12 |
2013-03-05 |
Threshold Pharmaceuticals Inc |
Administracion de profarmacos activados por hipoxia y de agentes antiangiogenicos para el tratamiento de cancer.
|
|
CA2818215C
(en)
|
2010-10-07 |
2015-07-21 |
Aerpio Therapeutics Inc. |
Compositions and methods for treating ocular edema, neovascularization and related diseases
|
|
EP2857032A3
(en)
|
2010-12-02 |
2015-07-15 |
Maruzen Pharmaceuticals Co., Ltd. |
Tie2 activator, vascular endothelial growth factor (vegf) inhibitor, anti-angiogenic agent, agent for maturing blood vessels, agent for normalizing blood vessels, agent for stabilizing blood vessels, and pharmaceutical composition
|
|
BR112014008759A8
(pt)
|
2011-10-13 |
2017-09-12 |
Aerpio Therapeutics Inc |
Tratamento de doença ocular
|
|
US20130095065A1
(en)
|
2011-10-13 |
2013-04-18 |
Aerpio Therapeutics, Inc. |
Methods for Treating Vascular Leak Syndrome and Cancer
|
|
US20130190324A1
(en)
|
2011-12-23 |
2013-07-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Topical ocular drug delivery
|
|
AU2013245630A1
(en)
|
2012-04-13 |
2014-10-30 |
The Johns Hopkins University |
Treatment of ischemic retinopathies
|
|
LT2880167T
(lt)
|
2012-07-31 |
2018-10-25 |
The Board Of Regents Of The University Of Texas System |
Kasos beta-ląstelių in vivo indukcijos būdai ir kompozicijos
|
|
CN104755103A
(zh)
|
2012-10-11 |
2015-07-01 |
阿森迪斯药物眼科部股份有限公司 |
用于治疗眼病症的中和vegf的前药
|
|
BR112015010566A2
(pt)
|
2012-11-08 |
2017-07-11 |
Clearside Biomedical Inc |
métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
|
|
WO2014079709A1
(en)
|
2012-11-23 |
2014-05-30 |
Ab Science |
Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
|
|
US9440963B2
(en)
|
2013-03-15 |
2016-09-13 |
Aerpio Therapeutics, Inc. |
Compositions, formulations and methods for treating ocular diseases
|
|
US20150050277A1
(en)
|
2013-03-15 |
2015-02-19 |
Aerpio Therapeutics Inc. |
Compositions and methods for treating ocular diseases
|
|
US10314882B2
(en)
|
2013-04-11 |
2019-06-11 |
Sunnybrook Research Institute |
Methods, uses and compositions of Tie2 agonists
|
|
US20160130321A1
(en)
|
2013-06-20 |
2016-05-12 |
Gabriela Burian |
Use of a vegf antagonist in treating macular edema
|
|
EP3010525A1
(en)
|
2013-06-20 |
2016-04-27 |
Novartis AG |
Use of a vegf antagonist in treating choroidal neovascularisation
|
|
WO2015002893A1
(en)
|
2013-07-02 |
2015-01-08 |
The Trustees Of Columbia University In The City Of New York |
Clearance of bioactive lipids from membrane structures by cyclodextrins
|
|
RU2676303C2
(ru)
|
2013-07-11 |
2018-12-27 |
Новартис Аг |
Использование антагониста vegf для лечения ретролентальной фиброплазии
|
|
EP3019526A1
(en)
|
2013-07-11 |
2016-05-18 |
Novartis AG |
Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
|
|
US9902767B2
(en)
|
2013-07-29 |
2018-02-27 |
Samsung Electronics Co., Ltd. |
Method of blocking vascular leakage using an anti-ANG2 antibody
|
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
|
JP6419794B2
(ja)
|
2013-10-01 |
2018-11-07 |
シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング |
主要な心臓有害事象に罹患する危険性を予測する方法
|
|
ES2727532T3
(es)
|
2013-11-01 |
2019-10-16 |
Regeneron Pharma |
Intervenciones basadas en angiopoyetina para el tratamiento de la malaria cerebral
|
|
US9388135B2
(en)
|
2014-02-19 |
2016-07-12 |
Aerpio Therapeutics, Inc. |
Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones
|
|
EP3116503A4
(en)
|
2014-03-14 |
2017-08-23 |
Aerpio Therapeutics, Inc. |
Hptp-beta inhibitors
|
|
JP2015199733A
(ja)
|
2014-04-04 |
2015-11-12 |
国立大学法人東北大学 |
眼圧降下剤
|
|
US9719135B2
(en)
|
2014-07-03 |
2017-08-01 |
Mannin Research Inc. |
Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
|
|
US9539245B2
(en)
|
2014-08-07 |
2017-01-10 |
Aerpio Therapeutics, Inc. |
Combination of immunotherapies with activators of Tie-2
|
|
US20160082129A1
(en)
|
2014-09-24 |
2016-03-24 |
Aerpio Therapeutics, Inc. |
VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
|
|
TWI806150B
(zh)
|
2014-11-07 |
2023-06-21 |
瑞士商諾華公司 |
穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
|
|
US20160144025A1
(en)
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
|
EP3977994B1
(en)
|
2015-09-23 |
2024-04-24 |
EyePoint Pharmaceuticals, Inc. |
Activators of tie-2 for use in treating intraocular pressure
|